Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era

Printer-friendly versionPrinter-friendly version

Article published in Human Vaccines & Immunotherapeutics on 21-February-2017 by Desai, Sachin N. et al. 


Cholera remains an important but neglected public health threat, affecting the health of the poorest populations and imposing substantial costs on public health systems. Cholera can be eliminated where access to clean water, sanitation, and satisfactory hygiene practices are sustained, but major improvements in infrastructure continue to be a distant goal. New developments and trends of cholera disease burden, the creation of an affordable cholera vaccine for use in developing countries, as well as recent evidence of vaccination impact has created an increased demand for oral cholera vaccine (OCV). The global OCV stockpile was established in 2013 and with support from Gavi, has assisted in achieving rapid access to vaccine in emergencies. Recent WHO prequalification of a second affordable OCV supports the stockpile goals of increased availability and distribution to affected populations. It serves as an essential step towards an integrated cholera control and prevention strategy in emergency and endemic settings.